Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 - ARTV News | RalliesArtiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026
A
ARTV• Planned data disclosures and milestones
- Artiva Biotherapeutics Inc. said it will disclose updated Phase 2a rheumatoid arthritis data from at least 20 patients in the second half of 2026.
- The company expects Phase 3 rheumatoid arthritis trial topline results by the end of 2028.
CLDI
•
